ONC Share Price Performance
Recent ONC News & Updates
No updates
Oncimmune Holdings plc Key Details
Last Reported Earnings
Aug 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.031
- Gross Margin
- 44.94%
- Net Profit Margin
- -127.71%
- Debt/Equity Ratio
- -211.2%
Oncimmune Holdings plc Competitors
About ONC
- Founded
- 2015
- Employees
- 40
- CEO
- WebsiteView website
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse event (irAE) prediction, patient screening, and diagnostic accuracy; Sero Tag, a discovery engine for the identification of relevant biomarker pool for target discovery or companion diagnostics; NavigAID for creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker. It also provides business development and marketing services. Oncimmune Holdings plc was incorporated in 2015 and is headquartered in Leeds, the United Kingdom.
U.K. Market Performance
- 7 Days: 0.3%
- 3 Months: 8.0%
- 1 Year: 6.7%
- Year to Date: 7.4%
The market has been flat in the last week, however the Healthcare sector is down 3.7%. Meanwhile, the market is actually up 6.7% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.
Continue readingLast Week
